192 related articles for article (PubMed ID: 20439986)
1. 3BP2 adapter protein is required for receptor activator of NFκB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells.
GuezGuez A; Prod'homme V; Mouska X; Baudot A; Blin-Wakkach C; Rottapel R; Deckert M
J Biol Chem; 2010 Jul; 285(27):20952-63. PubMed ID: 20439986
[TBL] [Abstract][Full Text] [Related]
2. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
3. SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.
Mukai T; Ishida S; Ishikawa R; Yoshitaka T; Kittaka M; Gallant R; Lin YL; Rottapel R; Brotto M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014 Dec; 29(12):2618-35. PubMed ID: 24916406
[TBL] [Abstract][Full Text] [Related]
4. 3BP2-deficient mice are osteoporotic with impaired osteoblast and osteoclast functions.
Levaot N; Simoncic PD; Dimitriou ID; Scotter A; La Rose J; Ng AH; Willett TL; Wang CJ; Janmohamed S; Grynpas M; Reichenberger E; Rottapel R
J Clin Invest; 2011 Aug; 121(8):3244-57. PubMed ID: 21765218
[TBL] [Abstract][Full Text] [Related]
5. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
6. Decreased SH3BP2 inhibits osteoclast differentiation and function.
Kawamoto T; Fan C; Gaivin RJ; Levine MA; Lietman SA
J Orthop Res; 2011 Oct; 29(10):1521-7. PubMed ID: 21448930
[TBL] [Abstract][Full Text] [Related]
7. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.
Hasegawa H; Kido S; Tomomura M; Fujimoto K; Ohi M; Kiyomura M; Kanegae H; Inaba A; Sakagami H; Tomomura A
J Biol Chem; 2010 Aug; 285(33):25448-57. PubMed ID: 20547767
[TBL] [Abstract][Full Text] [Related]
8. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of B-cell receptor signaling by a point mutation of adaptor protein 3BP2 identified in human inherited disease cherubism.
Ogi K; Nakashima K; Chihara K; Takeuchi K; Horiguchi T; Fujieda S; Sada K
Genes Cells; 2011 Sep; 16(9):951-60. PubMed ID: 21794028
[TBL] [Abstract][Full Text] [Related]
10. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation.
Sundaram K; Nishimura R; Senn J; Youssef RF; London SD; Reddy SV
Exp Cell Res; 2007 Jan; 313(1):168-78. PubMed ID: 17084841
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
12. Receptor activator of nuclear factor-kappaB ligand-induced mouse osteoclast differentiation is associated with switching between NADPH oxidase homologues.
Sasaki H; Yamamoto H; Tominaga K; Masuda K; Kawai T; Teshima-Kondo S; Matsuno K; Yabe-Nishimura C; Rokutan K
Free Radic Biol Med; 2009 Jul; 47(2):189-99. PubMed ID: 19409483
[TBL] [Abstract][Full Text] [Related]
13. Adaptor protein 3BP2 and cherubism.
Hatani T; Sada K
Curr Med Chem; 2008; 15(6):549-54. PubMed ID: 18336269
[TBL] [Abstract][Full Text] [Related]
14. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
[TBL] [Abstract][Full Text] [Related]
15. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
16. [The adaptor protein 3BP2 in leukocyte signaling].
Deckert M
Med Sci (Paris); 2006 Dec; 22(12):1081-6. PubMed ID: 17156730
[TBL] [Abstract][Full Text] [Related]
17. Mutations within the TNF-like core domain of RANKL impair osteoclast differentiation and activation.
Cheng T; Pavlos NJ; Wang C; Tan JW; Lin JM; Cornish J; Zheng MH; Xu J
Mol Endocrinol; 2009 Jan; 23(1):35-46. PubMed ID: 19008464
[TBL] [Abstract][Full Text] [Related]
18. RGS12 is essential for RANKL-evoked signaling for terminal differentiation of osteoclasts in vitro.
Yang S; Li YP
J Bone Miner Res; 2007 Jan; 22(1):45-54. PubMed ID: 17042716
[TBL] [Abstract][Full Text] [Related]
19. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells.
Hirotani H; Tuohy NA; Woo JT; Stern PH; Clipstone NA
J Biol Chem; 2004 Apr; 279(14):13984-92. PubMed ID: 14722106
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine phosphorylation of adaptor protein 3BP2 induces T cell receptor-mediated activation of transcription factor.
Qu X; Kawauchi-Kamata K; Miah SM; Hatani T; Yamamura H; Sada K
Biochemistry; 2005 Mar; 44(10):3891-8. PubMed ID: 15751964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
